Login / Signup

Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.

Selena Y CenDonald R Branch
Published in: Transfusion (2019)
Isoagglutinin-reduced Ig should have efficacy similar to nonreduced Ig and result in less IVIg-associated hemolysis.
Keyphrases
  • rheumatoid arthritis
  • mouse model
  • red blood cell
  • high dose
  • low dose
  • interstitial lung disease
  • ankylosing spondylitis
  • systemic sclerosis